Pediatric Bacterial Meningitis: 8 Essential Empiric Steps

Evaluate any infant or child with fever and one or more of the following for pediatric bacterial meningitis: altered mental status, neck stiffness or photophobia (older children), bulging fontanelle, petechial or purpuric rash, unexplained seizures, or unexplained shock.

In neonates and infants under 3 months with fever or hypothermia, include lumbar puncture as part of a full neonatal sepsis evaluation unless a clear contraindication exists — CSF should always be examined in this age group when sepsis is being investigated.

Obtain blood cultures (ideally two sets) and CSF cultures before antibiotics whenever it can be done within 30 minutes of presentation. If that window cannot be met, give antibiotics immediately and draw cultures alongside.

Order pre-LP head CT only when there are specific risk factors for cerebral herniation: focal neurologic deficits, GCS below 12, papilledema, a new-onset seizure within the past week, or significant immunocompromise. In their absence, perform the LP without imaging.

Document the time of antibiotic administration. Time-to-antibiotics is a central quality indicator in pediatric bacterial meningitis — institutional audits should track the proportion of cases treated within one hour of suspicion.

Start empiric IV antibiotics within 1 hour of suspecting pediatric bacterial meningitis. Each hour of delay beyond this point is associated with worsening neurologic outcomes and increased mortality.

For neonates aged 0–28 days, prescribe ampicillin 50 mg/kg IV every 6–8 hours (interval depends on postnatal age) plus cefotaxime 50 mg/kg IV every 6–8 hours. This pairing covers Group B Streptococcus, gram-negative enteric organisms (E. coli, Klebsiella), and Listeria monocytogenes.

For infants aged 1–3 months, prescribe ampicillin 75 mg/kg IV every 6 hours plus ceftriaxone 100 mg/kg IV daily (or split 50 mg/kg every 12 hours), maximum 4 g/day. This regimen bridges late-neonatal Listeria coverage with the community organisms of older infancy.

For children older than 3 months, prescribe ceftriaxone 100 mg/kg IV daily (max 4 g, split 12-hourly if dose exceeds 2 g) plus vancomycin 15–20 mg/kg IV every 6 hours (max 60 mg/kg/day, target trough 15–20 mcg/mL). Vancomycin is added empirically because cephalosporin-resistant pneumococcus is common enough to warrant cover until susceptibilities return.

For a child with documented penicillin allergy and no cephalosporin cross-reactivity, ceftriaxone remains preferred. In the unusual case of true beta-lactam allergy, substitute vancomycin plus a fluoroquinolone (moxifloxacin) or chloramphenicol where available — consult pediatric infectious diseases urgently.

Add ampicillin to the empiric regimen for any pediatric patient with significant immunocompromise (oncology, transplant, congenital immunodeficiency) regardless of age — Listeria remains a concern.

Do not co-administer ceftriaxone with calcium-containing IV fluids in neonates — fatal calcium-ceftriaxone precipitates have been reported in the lungs and kidneys. Use cefotaxime in neonates whenever calcium-containing solutions are needed.

Narrow therapy to the most targeted agent as soon as the organism and susceptibilities return. For a fully cephalosporin-susceptible pneumococcus, vancomycin can usually be discontinued and ceftriaxone continued alone.

Give dexamethasone 0.15 mg/kg IV (maximum 10 mg per dose) immediately before or together with the first antibiotic dose in children older than 6 weeks with suspected or confirmed Hib meningitis — particularly relevant in children with an incomplete Hib vaccine schedule. Continue every 6 hours for 4 days.

Consider dexamethasone for suspected or confirmed pneumococcal meningitis in children — meta-analyses suggest a reduction in severe hearing loss when steroids are given before or with the first antibiotic dose, though the magnitude of benefit is smaller than for Hib disease.

Do not give dexamethasone to neonates with bacterial meningitis — there is no evidence of benefit in this age group, and developmental concerns argue against routine corticosteroid exposure.

Do not start dexamethasone more than 4 hours after the first antibiotic dose — once bacterial lysis is well underway, modulating the inflammatory response with steroids no longer alters outcome.

Discontinue dexamethasone early if cultures and CSF PCR exclude bacterial meningitis or another non-bacterial diagnosis becomes apparent. There is no role for completing the full 4-day course in viral meningoencephalitis.

Identify close contacts of a meningococcal index case within 24 hours. Close contacts include household members, anyone who shared sleeping quarters in the 7 days before symptom onset, regular childcare or preschool contacts, and anyone with direct mucosal exposure to oral secretions (kissing, mouth-to-mouth resuscitation, unprotected intubation).

Prescribe rifampin 10 mg/kg PO every 12 hours (maximum 600 mg per dose) for 2 days as first-line meningococcal chemoprophylaxis in children. For neonates under 1 month, use 5 mg/kg every 12 hours.

Use ceftriaxone 125 mg IM as a single dose (children younger than 15 years) or 250 mg IM (15 years and older) as an alternative — especially useful for pregnant contacts and for ensuring a single observed dose. Ciprofloxacin 20 mg/kg PO as a single dose (max 500 mg) is another option for children who can swallow tablets. Use the exposure as a chance to review and update meningococcal vaccination.

For invasive Hib disease, prescribe rifampin 20 mg/kg/day PO (max 600 mg/day) for 4 days to all unvaccinated or incompletely vaccinated household contacts younger than 4 years. Treat all household members — including fully vaccinated adults — when the household contains an immunocompromised child regardless of that child’s vaccination status.

Do not give chemoprophylaxis to contacts of children with pneumococcal meningitis. Secondary attack rates are not increased above background, and prophylaxis has not been shown to prevent transmission.

Repeat lumbar puncture 24–48 hours after starting therapy only when the clinical course is atypical, the patient is not improving, or the isolate is resistant or unusual. Routine repeat LP is not required in straightforward courses.

Arrange formal audiology follow-up within 4–6 weeks of discharge. Sensorineural hearing loss occurs in 5–30% of bacterial meningitis survivors, with the highest risk after pneumococcal disease. Early identification supports timely amplification or cochlear implantation referral.

Plan neurodevelopmental review at 6 and 12 months post-discharge for any child who survived pediatric bacterial meningitis. Screen specifically for motor delay, language regression, behavioral change, and new-onset epilepsy.

Review the child’s immunization record and bring all vaccines up to date before discharge, with particular attention to PCV, Hib, and meningococcal conjugate vaccines. Use the admission as a catch-up opportunity for household contacts as well.